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. Using a tamoxifen-inducible Pkd1 conditional knockout, Piontek et al. 36 showed that when Pkd1 inactivation occurred before postnatal day 13, the mice developed severely cystic kidneys, whereas inactivation after postnatal day 13 resulted in only late onset cysts. Independently, Lantingavan-Leeuwen et al. 26 and Takakura et al. 37 , demonstrated PC1 maturation depends on its cleavage and posttranslational modifications that results in a glycosylated PC1 N-terminal product (PC1-NTR). Interestingly, PC1/ PC2 interaction seems to be essential in this process.
According to Chapin et al., PC2 expression is crucial to both PC1 GPS cleavage and PC1 appearance at the plasma and ciliary membrane. Mutations that prevent GPS-dependent PC1 cleavage hinder its plasma membrane localization 42 . A later study showed that PC1 and PC2 initially interact in the ER before GPS cleavage and that this interaction is central to the subsequent PC1 maturation, including exiting from the endoplasmic reticulum and cell surface localization.
In this process, PC2 acts as an essential chaperone for PC1 maturation 43 . A hypomorphic mouse model (Pkd1 RC/ RC ) that develops gradual cystogenesis displays reduced levels of PC1-NTR in renal tissue and urinary exosomelike vesicles 34 , supporting an essential role of mature PC1 in kidney maintenance.
Cardiovascular dysfunction in ADPKD
Several studies have demonstrated that cardiovascular alterations seem to initiate early in the course of ADPKD and constitute a major cause of morbidity and mortality in this disease 44, 45 . In this context, The mTOR (mammalian target of rapamycin) signaling pathway is essential for cell growth, proliferation and survival. This pathway is upregulated in cyst-lining cells both in patients and in animal models of ADPKD. In several pre-clinical studies, mTOR inhibitors ameliorated cystic disease progression [69] [70] [71] [72] . Based on this knowledge, two independent large clinical trials were performed in ADPKD patients using mTOR inhibitors 73, 74 . Such trials targeted patients within different ranges of renal function.
Disappointing results were obtained, however, as mTOR inhibition did not show significant effects on disease progression in both studies. Dose limiting due to side effects may have contributed to the lack of clinical success.
As observed, biological differences between humans and rodents and the complexity of the signaling-pathway network related to ADPKD are significant challenges to overcome in translating data and information from the preclinical to the clinical reality. Combined treatment with a number of agents, however, may become an effective therapy in the future, since this approach could be potentially applied using lower doses, avoiding unwanted adverse effects, while promoting additive beneficial effects.
Future technologies and perspectives
Possibilities of genetic engineering have become more efficient and cost-effective. Notably, the CRISPR/ Cas-9 platform allows the generation of specific knockout mice in six months 75 . This system uses an artificial guide RNA complementary to the genomic target sequence conjugated to a bacterial protein capable of activating These approaches, however, are still far from reproducing the complexity of in vivo models, emphasizing the pivotal contributions and need of animals models for the next decades.
Despite the relevant knowledge accumulation in ADPKD molecular pathogenesis, the genetic interactions and cellular pathways are still largely unknown. The current data suggest PKD1 and PKD2 participation in dynamic and integrative ways, varying according to the cellular and systemic status. Modern technologies allow control of the time, tissue and pattern of gene inactivation in a relatively fast and available fashion. This setting facilitates the generation of animals carrying multiple geneticallyengineered alleles, enabling the investigation of genetic interactions in different stages of development, in kidney injury, and in other strategic conditions. This approach may be allied to the use of modern reporter genes, allowing more precise tracking of cellular recombination events. The application of network expression platforms, in turn, has the potential of returning a comprehensive view and critical analysis of alterations in the cell pathway network. Such possibilities are likely to favor the identification of ADPKD modifier loci and new potential therapeutic targets.
Recently developed in vitro approaches such as the kidney-on-a-chip and kidney organoid technologies may also provide additional robust and complementary inputs to the comprehension and treatment of ADPKD. Along these lines, in the next decades the scientific community and patients will likely experience a dramatic improvement in ADPKD understanding and intervention, provided by the successive steps of molecular and cellular translational medicine. 
